A number of biotech companies, including Gilead Sciences , have staked a lot on CAR-T therapies for cancer patients. Today, Guggenheim's Tony Butler and his team take a look at the debate about one set of side effects for these treatments, but ultimately they don't think they'll slow the adoption of these options.
Original Article: Treatment Debates Won't Slow Down Biotechs